Tacrine

CHEMBL95 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
198.3 g/mol
LogP
2.7
Phase
4

Tacrine (tetrahydroaminoacridine, THA) is a first-generation reversible acetylcholinesterase inhibitor used historically for symptomatic treatment of mild-to-moderate Alzheimer's disease, acting by inhibiting both acetylcholinesterase (AChE) and butyrylcholinesterase to increase acetylcholine levels in cholinergic synapses in the cortex and hippocampus. It also has additional activities including NMDA receptor antagonism, potassium channel blockade, and monoamine oxidase inhibition. Due to high hepatotoxicity risk and the availability of better-tolerated cholinesterase inhibitors, it has been largely discontinued.

Khối lượng phân tử

198,2600 g/mol

LogP

2,70

TPSA

38,90 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Nc1c2c(nc3ccccc13)CCCC2

InChI

InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)

Molecular Formula

C13H14N2

HBD / HBA

1 / 2

Liên kết có thể quay

0

Nguyên tử nặng

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Tacrine (tetrahydroaminoacridine, THA) is a first-generation reversible acetylcholinesterase inhibitor used historically for symptomatic treatment of mild-to-moderate Alzheimer's disease, acting by inhibiting both acetylcholinesterase (AChE) and butyrylcholinesterase to increase acetylcholine levels in cholinergic synapses in the cortex and hippocampus. It also has additional activities including NMDA receptor antagonism, potassium channel blockade, and monoamine oxidase inhibition. Due to high hepatotoxicity risk and the availability of better-tolerated cholinesterase inhibitors, it has been largely discontinued.

Inhibits acetylcholinesterase, the enzyme that hydrolyzes acetylcholine in the synaptic cleft. This increases acetylcholine availability at cholinergic synapses, enhancing cholinergic neurotransmission.

Yes, Tacrine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL95. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 1935. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.